|
Addressing the Cardiometabolic Risk Continuum in MASH: What Clinicians Need to Know |
- 1.00 CDE
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
|
Clinical Brief: Advancements in Dyslipidemia Treatments and ASCVD Risk Reduction for High-Risk Individuals |
- 0.50 CDE
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
|
Enduring |
|
$0.00 |
|
Navigating Cardiorenal Metabolic Complexities: A Case Study of a 64-Year-Old Female with T2D, HTN, CKD, and Obesity |
- 0.50 CDE
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
|
Enduring |
|
$0.00 |
|
Navigating the Latest in Pulmonary Arterial Hypertension: Implementing Guidelines Amidst a Changing Treatment Landscape |
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
|
Enduring |
|
$0.00 |
|
Integrating CGM with GLP-1 RA Therapy: Clinical Evidence, Treatment a Overcoming Barriers in T2DM |
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
|
Enduring |
|
$0.00 |
|
MASH Uncovered: Essential Insights for Clinicians on Effective Screening, Risk Stratification, and Disease Management |
- 1.25 CDE
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation
|
Enduring |
|
$0.00 |
|
Innovative Approaches to Managing Resistant/Uncontrolled Hypertension: Screening, Evaluation and Intervention |
- 0.75 CDE
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
|
Enduring |
|
$0.00 |